Buy Brown & Brown on Dips: Acquisitions Should Re-accelerate EPS Over the Next Quarter

Hook and thesis

Brown & Brown (NYSE: BRO) has been punished by the market over the last year, yet the operational story that matters to shareholders remains intact: disciplined, accretive acquisitions plus high client retention are pushing adjusted margins and EPS higher. Management’s recent integrations - most notably Accession - lifted total revenues and adjusted EPS in 2025 while free cash flow remains strong at $1.446 billion. That combination argues for a tactical long on weakness with defined risk limits.

My trade thesis is simple: buy the company now for a mid-term play (45 trading days) to capture re-rating and earnings accretion as acquisition synergies become visible in reported results and guidance. The entry is tactical because interest-rate pressure and elevated debt are real drawbacks. Still, valuation measures and cash generation support upside to the $75 level if the company sustains commission growth and controls expense leverage.

What Brown & Brown does and why the market should care

Brown & Brown is an insurance intermediary: it operates Retail, Specialty Distribution and Other segments, offering brokerage, wholesale brokerage and program underwriting services. The business model is predictable: recurring commissions and fees, strong client retention, and inorganic growth through acquisitions. That model scales well - add a bolt-on agency, fold in distribution, and the incremental margin on acquired revenue is typically high after integration.

Why investors should care now: the company reported strong total revenues of $1.6 billion in Q4 2025 (up 35.7% YoY) and full-year 2025 revenues of $5.9 billion (up 22.8%), driven by the Accession acquisition. Adjusted diluted EPS for 2025 was reported at $4.26, and trailing free cash flow is $1.446 billion. Those are not small numbers - they show the firm is still generating healthy cash while using M&A to grow scale and margins.

Supporting numbers

• Current price: $65.02; 52-week range: $53.81 - $96.55.
• Market capitalization: $21.76 billion; enterprise value: $28.60 billion.
• Reported trailing metrics: EPS in the ratios table shows $3.56, while management reported adjusted diluted EPS of $4.26 for 2025.
• Valuation: P/E roughly in the high teens to ~20 depending on the EPS series; EV/EBITDA 16.4; price-to-book ~1.73; price-to-sales ~3.26.
• Balance sheet and cash flow: free cash flow $1.446 billion and debt-to-equity 0.62. News filings note total debt around the mid-single-digit billions following recent financing for Accession.
• Technicals: RSI ~35 suggests the stock is nearer to oversold than overbought; MACD signals bearish momentum but the short-term moving averages are below the 20/50-day averages.

Valuation framing

On simple multiples, Brown & Brown trades at a reasonable multiple for a private-equity-like roll-up: P/E in the high teens, EV/EBITDA ~16.4 and price-to-book near 1.7. That pricing reflects the market discount for leverage and interest-cost risk rather than doubts about core underwriting or retention. For a company generating $1.45 billion in free cash flow, an enterprise value of roughly $28.6 billion implies a free-cash-flow yield that is not demanding if management can sustain mid-single-digit organic growth plus accretion from tuck-in deals.

Compare the current price to the 52-week high of $96.55 and the low of $53.81. The stock has already retraced materially from peak levels; some of that decline is valuation compression rather than a collapse in fundamentals. If the next quarterly report shows sequential improvement in commission growth and stable adjusted margins, re-rating toward a mid-teens EV/EBITDA multiple is reasonable. That’s the gap the trade targets.

Catalysts (what will drive the trade)

• Quarterly results showing acquisition synergies feeding through to adjusted EPS and margins - management flagged accretion after Accession in Q4 2025 (reported 01/26/2026).
• Any positive commentary on interest cost trajectory or refinancing activity that reduces near-term interest expense pressure.
• Additional tuck-in acquisitions announced or closed that are clearly accretive and accompanied by integration timelines and expected synergies.
• Evidence of revenue retention and cross-sell gains driven by investments in technology and AI referenced by management during prior investor calls.

Trade plan - Entry, targets, stop, and horizon

Actionable trade (mid-term):

• Direction: Long.
• Entry price: $64.00.
• Target price: $75.00.
• Stop loss: $60.00.
• Horizon: mid term (45 trading days). Expect the trade to last about 45 trading days to give time for catalyst flow - Q3 commentary, any follow-on tuck-ins, or a technical bounce as momentum indicators stabilize.

Rationale: $64 is slightly below the most recent trade and gives room for short-term volatility while avoiding chasing the intraday highs. The $75 target is achievable if the market revisits a P/E of 18-20 on improving adjusted EPS, and it offers roughly 15% upside from the $65 area. The $60 stop caps downside to roughly 7-8% and respects the $53.81 52-week low as a deeper support zone; cutting losses well before structural deterioration is prudent given interest-cost sensitivity.

Risks and counterarguments

Below are the principal risks that could derail this thesis and the trade, followed by a counterargument to my own bullish stance.

• Interest-cost shock: The company financed part of Accession; elevated interest expense (reported as rising ~96% in recent commentary) could continue to compress margins and depress adjusted EPS if rates remain elevated.
• Integration execution risk: Acquisitions are only as good as the integration. Defections and staff losses are not hypothetical - the firm disclosed a material employee defection that cost ~$23 million of annual revenue. Further defections could hurt organic revenue and synergies.
• Leverage and refinancing risk: While debt-to-equity sits near 0.62, refinancing risk and covenant pressure could arise if free cash flow weakens or M&A pipeline slows.
• Macro pressure on commercial lines: An economic slowdown could reduce new business generation and hit commission volumes, turning revenue momentum negative in the near term.
• Sentiment and momentum: Technical indicators (MACD bearish, RSI near 35) and high short interest at times leave the stock vulnerable to momentum-driven downside.

Counterargument: A reasonable bear case is that the market is correctly pricing a persistent rise in interest expense that will offset acquisition accretion for multiple quarters, keeping adjusted EPS growth muted. If macro-driven organic revenue weakness persists, free cash flow could contract and elevate refinancing risk, justifying further multiple compression.

Why I still favor the trade

Despite the risks above, the company’s demonstrated ability to generate $1.446 billion in free cash flow and to deliver adjusted EPS accretion after acquisitions makes a mid-term trade attractive. The valuation already reflects some discount for leverage and execution risk - P/E in the high teens and EV/EBITDA ~16.4 is not demanding for a business with stable recurring revenue if management can show even modest improvements in margin and commission growth. The stop at $60 protects capital against the scenario where interest costs or integration failures prove worse than expected.

What would change my mind

I would close the long and turn neutral or bearish if any of the following occur within the next 45 trading days:

• A quarterly report that shows continued organic revenue decline without offsetting acquisition accretion and a material downward revision to adjusted EPS guidance.
• Clear evidence of larger-than-disclosed defections or integration failures that meaningfully depress revenue retention metrics.
• A refinancing announcement that increases gross interest expenses materially beyond current market expectations or triggers covenant issues.

Bottom line

Brown & Brown is a well-capitalized consolidator in the insurance brokerage space with a proven M&A model, strong free cash flow, and recent evidence of margin expansion after Accession. The market is focused on interest-cost and integration risks, which is reasonable, but the combination of reasonable valuation, recurring cash flow and the potential for acquisition-led EPS upside supports a tactical long. Enter at $64, target $75 over 45 trading days, and use a $60 stop to manage the headline risks described above.

Key metrics summary

Trade idea: long Brown & Brown. Entry $64.00, target $75.00, stop $60.00. Horizon: mid term (45 trading days).